Montag, 26. Oktober 2020
Navigation öffnen

SchwerpunktJuli 2020

01. Juli 2020
Seite 9/9




1. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Aktinische Keratose und Plattenepithelkarzinom der Haut, Langversion 1.0, 2019, AWMF Registernummer: 032/022OL, (abgerufen am: 05.05.2020)
2. Leiter U, Keim U, Eigentler T et al. Incidence, Mortality, and Trends of Nonmelanoma Skin Cancer in Germany. J Invest Dermatol 2017. doi:10.1016/j.jid.2017.04.020.
3. Schäfer I, Reusch M, Siebert J et al. Health care characteristics of basal cell carcinoma in Germany: The role of insurance status and socio-demographic factors. JDDG – J Ger Soc Dermatology 2014. doi:10.1111/ddg.12415.
4. Hommel T, Szeimies R-M. Aktinische Keratosen – Actinic keratoses. Der Onkologe 2017. doi:10.1007/s00761-017-0189-7.
5. Green AC. Epidemiology of actinic keratoses. Curr Probl Dermatol 2015. doi:10.1159/000366525.
6. Memon AA, Tomenson JA, Bothwell J et al. Prevalence of solar damage and actinic keratosis in a Merseyside population. Br J Dermatol 2000. doi:10.1046/j.1365-2133.2000.03541.x.
7. Lai V, Cranwell W, Sinclair R. Epidemiology of skin cancer in the mature patient. Clin Dermatol 2018. doi:10.1016/j.clindermatol.2017.10.008.
8. Stang A, Khil L, Kajüter H et al. Incidence and mortality for cutaneous squamous cell carci-noma: comparison across three continents. J Eur Acad Dermatol Venereol 2019. doi:10.1111/jdv.15967.
9. O’Reilly Zwald F, Brown M. Skin cancer in solid organ transplant recipients: Advances in therapy and management: Part I. Epidemiology of skin cancer in solid organ transplant recipients. J Am Acad Dermatol 2011. doi:10.1016/j.jaad.2010.11.063.
10. Berg D, Otley CC. Skin cancer in organ transplant recipients: Epidemiology, pathogenesis, and management. J Am Acad Dermatol 2002. doi:10.1067/mjd.2002.125579.
11. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003. doi:10.1056/NEJMra022137.
12. Ulrich C, Schmook T, Nindl I et al. Cutaneous precancers in organ transplant recipients: An old enemy in a new surrounding. In: Br J Dermatol Suppl 2003. doi:10.1046/j.0366-077x.2003.05633.x.
13. Nashan D, Radny P, Kösters NC et al. Hauttumoren transplantierter Patienten – Skin tumors in organ-transplant recipients. Der Hautarzt 2007. doi:10.1007/s00105-006-1159-y.
14. Schmitt J, Seidler A, Diepgen TL et al. Occupational ultraviolet light exposure increases the risk for the development of cutaneous squamous cell carcinoma: A systematic review and meta-analysis. Br J Dermatol 2011. doi:10.1111/j.1365-2133.2010.10118.x.
15. Diepgen TL. New developments in occupational dermatology. JDDG – J Ger Soc Dermatol 2016. doi:10.1111/ddg.13128.
16. Bauer A. Hautkrebs als Berufserkrankung. Hautarzt 2016. doi:10.1007/s00105-016-3877-0.
17. Fernández-Figueras MT, Carrato C, Sáenz X et al. Actinic keratosis with atypical basal cells (AK I) is the most common lesion associated with invasive squamous cell carcinoma of the skin. J Eur Acad Dermatol Venereol 2015. doi:10.1111/jdv.12848.
18. Schmitz L, Gambichler T, Gupta G et al. Actinic keratoses show variable histological basal growth patterns – a proposed classification adjustment. J Eur Acad Dermatol Venereol 2018. doi:10.1111/jdv.14512.
19. Keurentjes AJ, de Witt KD, Jakasa I et al. Actinic keratosis and surrounding skin exhibit changes in corneocyte surface topography and decreased levels of filaggrin degradation products. Exp Dermatol 2020. doi:10.1111/exd.14089.
20. Kauczok C. Aktinische Keratosen: Diagnostik und Therapie aus histologischer Sicht. Ärztliches J Onkol 2017;3.
21. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). S3-Leitlinie Prävention von Hautkrebs, Langversion 1.1. AWMF Registernummer: 032/052OL, (Zugriff am 05.05.2020).
22. Buller DB, Berwick M, Lantz K et al. Evaluation of immediate and 12-week effects of a smartphone sun-safety mobile application: A randomized clinical trial. JAMA Dermatol 2015.
23. Breitbart EW, Waldmann A, Nolte S et al. Systematic skin cancer screening in Northern Germany. J Am Acad Dermatol 2012. doi:10.1016/j.jaad.2010.11.016.
24. Waldmann A, Nolte S, Weinstock MA et al. Skin cancer screening participation and impact on melanoma incidence in Germany – an observational study on incidence trends in regions with and without population-based screening. Br J Cancer 2012. doi:10.1038/bjc.2012.22.
25. Werner RN, Sammain A, Erdmann R et al. The natural history of actinic keratosis: A systematic review. Br J Dermatol 2013. doi:10.1111/bjd.12420.
26. Zouboulis CC, Röhrs H. Kryochirurgische behandlung aktinischer Keratosen mit evidenzbasierter Übersicht. Hautarzt 2005. doi:10.1007/s00105-004-0865-6.
27. Thai KE, Fergin P, Freeman M et al. A prospective study of the use of cryosurgery for the treatment of actinic keratoses. Int J Dermatol 2004. doi:10.1111/j.1365-4632.2004.02056.x.
28. De Oliveira MC, Pinto CAL, Pinto JCCL et al. Histopathological analysis of the therapeutic response to cryotherapy with liquid nitrogen in patients with multiple actinic keratosis. An Bras Dermatol 2015;90(3):384-389. doi:10.1590/abd1806-4841.20153302.
29. Steeb T, Wessely A, Leiter U et al. The more the better? An appraisal of combination therapies for actinic keratosis. J Eur Acad Dermatol Venereol 2019. doi:10.1111/jdv.15998.
30. Speiser JJ, Garib G, Novice K et al. Actinic keratosis, transected: what lies beneath? Am J Dermatopathol 2015. doi:10.1097/DAD.0000000000000366.
31. Övermark M, Koskenmies S, Pitkänen S. A retrospective study of treatment of squamous cell carcinoma in situ. Acta Derm Venereol 2016. doi:10.2340/00015555-2175.
32. Pflugfelder A, Welter AK, Leiter U et al. Open label randomized study comparing 3 months vs. 6 months treatment of actinic keratoses with 3% diclofenac in 2.5% hyaluronic acid gel: A trial of the German Dermatologic Cooperative Oncology Group. J Eur Acad Dermatol Venereol 2012. doi:10.1111/j.1468-3083.2011.04005.x.
33. Jansen MHE, Kessels JPHM, Nelemans PJ et al. Randomized trial of four treatment approa-ches for actinic keratosis. N Engl J Med 2019. doi:10.1056/NEJMoa1811850.
34. Stockfleth E, von Kiedrowski R, Dominicus R et al. Efficacy and Safety of 5-Fluorouracil 0.5%/Salicylic Acid 10% in the Field-Directed Treatment of Actinic Keratosis: A Phase III, Randomized, Double-Blind, Vehicle-Controlled Trial. Dermatol Ther (Heidelb) 2017;7(1):81-96. doi:10.1007/s13555-016-0161-2.
35. Stockfleth E, Kerl H, Zwingers T et al. Low-dose 5-fluorouracil in combination with salicylic acid as a new lesion-directed option to treat topically actinic keratoses: Histological and clinical study results. Br J Dermatol 2011. doi:10.1111/j.1365-2133.2011.10387.x.
36. Vegter S, Tolley K. A network meta-analysis of the relative efficacy of treatments for actinic keratosis of the face or scalp in Europe. PLoS One 2014. doi:10.1371/journal.pone.0096829.
37. Askew DA, Mickan SM, Soyer HP et al. Effectiveness of 5-fluorouracil treatment for actinic keratosis – A systematic review of randomized controlled trials. Int J Dermatol 2009. doi:10.1111/j.1365-4632.2009.04045.x.
38. Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM). Picato® (Ingenolmebutat): Bewertung des Nutzen-Risiko-Verhältnisses. Accessed May 5, 2020.
39. Hauschild A, Popp G, Stockfleth E et al. Effective photodynamic therapy of actinic keratoses on the head and face with a novel, self-adhesive 5-aminolaevulinic acid patch. Exp Dermatol 2009. doi:10.1111/j.1600-0625.2008.00770.x.
40. Dirschka T, Ekanayake-Bohlig S, Dominicus R et al. A randomized, intraindividual, noninferiority, Phase III study comparing daylight photodynamic therapy with BF-200 ALA gel and MAL cream for the treatment of actinic keratosis. J Eur Acad Dermatology Venereol 2019;33(2):288-297. doi:10.1111/jdv.15185.
41. Szeimies RM. Pain perception during photodynamic therapy: Why is daylight PDT with methyl aminolevulinate almost pain-free? A review on the underlying mechanisms, clinical reflections and resulting opportunities. G Ital di Dermatologia e Venereol 2018. doi:10.23736/S0392-0488.18.06011-X.
42. Mordon S. Painless and efficient ALA-PDT and MAL-PDT of Actinic Keratosis can be achieved by drastically reducing the Drug-Light Interval (DLI). Dermatol Ther 2020;e13423. doi:10.1111/dth.13423.
43. Wiegell SR, Wulf HC, Szeimies RM et al. Daylight photodynamic therapy for actinic keratosis: An international consensus: International Society for Photodynamic Therapy in Dermatology. J Eur Acad Dermatol Venereol 2012. doi:10.1111/j.1468-3083.2011.04386.x.
44. Reinhold U, Dirschka T, Ostendorf R et al. A randomized, double-blind, phase III, multicentre study to evaluate the safety and efficacy of BF-200 ALA (Ameluz®) vs. placebo in the field-directed treatment of mild-to-moderate actinic keratosis with photodynamic therapy (PDT) when using the BF-RhodoL. Br J Dermatol 2016. doi:10.1111/bjd.14498.
45. Szeimies RM, Radny P, Sebastian M et al. Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: Results of a prospective,
randomized, double-blind, placebocontrolled phase III study. Br J Dermatol 2010. doi:10.1111/j.1365-2133.2010.09873.x.
46. West CE, Kwatra SG, Choi J et al. A novel plant-derived compound is synergistic with 5-fluorouracil and has increased apoptotic activity through autophagy in the treatment of actinic keratoses. J Dermatolog Treat 2020. 10.1080/09546634.2020.1764905.
47. Cramer P, Stockfleth E. Actinic keratosis: where do we stand and where is the future going to take us? Expert Opin Emerg Drugs. 2020;25(1):49-58. doi:10.1080/14728214.20 20.1730810.
48. Cuevas Sánchez P, Espinoza W, Pérez C et al. Topical treatment of actinic keratoses with potassium dobesilate 5% cream. A preliminary open-label study. Eur J Med Res 2011. doi:10.1186/2047-783x-16-2-67.
49. Guorgis G, Anderson CD, Lyth J et al. Actinic Keratosis Diagnosis and Increased Risk of Developing Skin Cancer: A 10-year Cohort Study of 17,651 Patients in Sweden 1. Acta Derm Venereol 2020;(12):1-6. doi:10.2340/00015555- 3486.
50. Figueras Nart I, Cerio R, Dirschka T et al. Defining the actinic keratosis field: a literature re-view and discussion. J Eur Acad Dermatol Venereol 2018. doi:10.1111/jdv.14652.
51. Heppt MV, Steeb T, Schmitz L et al. Harmonisation of Outcome Parameters and Evaluation (HOPE) for actinic keratosis: Protocol for the development of a core outcome set. Trials 2019. doi:10.1186/s13063-019-3696-6.

Nächste Seite

Medical Cloud

Sie können folgenden Inhalt einem Kollegen empfehlen:

"Aktinische Keratosen"

Bitte tragen Sie auch die Absenderdaten vollständig ein, damit Sie der Empfänger erkennen kann.

Die mit (*) gekennzeichneten Angaben müssen eingetragen werden!

Die Verwendung Ihrer Daten für den Newsletter können Sie jederzeit mit Wirkung für die Zukunft gegenüber der rsmedia GmbH widersprechen ohne dass Kosten entstehen. Nutzen Sie hierfür etwaige Abmeldelinks im Newsletter oder schreiben Sie eine E-Mail an: info[at]

  • Erster Lockdown seit Monaten – Ab 14 Uhr dürfen die Berchtesgadener nur noch aus trifftigen Gründen ihre Wohnungen verlassen (dpa, 20.10.2020).
  • Erster Lockdown seit Monaten – Ab 14 Uhr dürfen die Berchtesgadener nur noch aus trifftigen Gründen ihre Wohnungen verlassen (dpa, 20.10.2020).